On July 29, Tianjin Pharmaceutical Group Co., Ltd. issued an announcement stating that its subsidiary, Tianjin Pharmaceutical Peace Co., Ltd., received the "Approval Notice for Supplementary Application for Drug" issued by the National Medical Products Administration, approving the product to pass the consistency evaluation of generic drug quality and efficacy.

It is understood that this product is suitable for patients with acute and chronic renal failure who require continuous ambulatory peritoneal dialysis treatment due to ineffective non-dialysis therapies. In June 2025, Tianjin Pharmaceutical Group's Heping low-calcium peritoneal dialysis solution passed the generic drug consistency evaluation. This time, the approval of two peritoneal dialysis solutions (lactate) will further enhance the market competitiveness of the company's peritoneal dialysis solution product line.

Articles: Board Office of Tianjin Pharmaceutical Group Co., Ltd., China Securities Journal (China Securities Network)